2.7Impact Factor
4.5CiteScore
23 daysTime to First Decision

Antibodies, Volume 10, Issue 3

September 2021 - 12 articles

Cover Story: T cell therapies, including CAR T cells, have proven more effective in hematologic malignancies than solid tumors, where the local metabolic environment is distinctly immunosuppressive. We discuss how intrinsic- (T cells) as well as extrinsic (tumor cells and micro-environmental)-derived metabolic factors, including lactate, suppress the ability of antigen-specific T cells to eradicate tumors. Finally, we introduce recent discoveries that target the TME in order to potentiate T cell-based therapies against cancer. View this paper

Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
You may sign up for email alerts to receive table of contents of newly released issues.
PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (12)

Select all

Review

49 Citations

9,287 Views

12 Pages

Beyond the Lactate Paradox: How Lactate and Acidity Impact T Cell Therapies against Cancer

Violet Y. Tu,
Asma Ayari and
Roddy S. O’Connor

Antibodies2021, 10(3), 25;https://doi.org/10.3390/antib10030025

28 June 2021

T cell therapies, including CAR T cells, have proven more effective in hematologic malignancies than solid tumors, where the local metabolic environment is distinctly immunosuppressive. In particular, the acidic and hypoxic features of the tumor micr...

Full Article

Article

7 Citations

4,534 Views

13 Pages

Higher PD-L1 Immunohistochemical Detection Signal in Frozen Compared to Matched Paraffin-Embedded Formalin-Fixed Tissues

Hazem Ghebeh,
Fatmah A. Mansour,
Dilek Colak,
Akram A. Alfuraydi,
Amal A. Al-Thubiti,
Dorota Monies,
Monther Al-Alwan,
Taher Al-Tweigeri and
Asma Tulbah

Antibodies2021, 10(3), 24;https://doi.org/10.3390/antib10030024

22 June 2021

Purpose: Response to anti-PD-L1/PD-1 immunotherapy correlates with PD-L1 expression in breast cancer. However, the prevalence of PD-L1 positive breast cancer is variable, which could be due to differences in the population/cohort of patients tested o...

Full Article

of 2

Get Alerted

Add your email address to receive forthcoming issues of this journal.

Antibodies - ISSN 2073-4468

Imprint

Download Flyer